$VBIV News
Last published 2y ago
- 2y agoVBIVVBI Vaccines Provides an Update on its Restructuring ProceedingsBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided an update on the restructuring proceedings announced
- 2y agoVBIVVBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic AlternativesBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the Ontario Superior Court of Justice
- 2y agoVBIVVBI Vaccines Announces Results of Annual General MeetingBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting
- 2y agoVBIVVBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma PatientsBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the
- 2y agoVBIVVBI Vaccines Reports First Quarter 2024 Financial ResultsBusiness WirePreHevbrio® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from
- 2y agoVBIVVBI Vaccines Reports Full Year 2023 Financial ResultsBusiness WirePreHevbrio® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 234% year-over-year from 2022 to 2023 Preliminary 2024 PreHevbrio U.S. sales demonstrate continued growth, with approximately 65% of
- 2y agoVBIVVBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the closing of its previously announced registered
- 2y agoVBIVVBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has entered into definitive agreements for
- 2y agoVBIVVBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent GlioblastomaBusiness WireData highlighted in oral presentation at World Vaccine Congress 2024 on April 3, 2024 Early data from patients eligible for evaluation at week 12 show two observations of stable disease, indicating no tumor
- 2y agoVBIVVBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine PlatformBusiness WireVBI Vaccines and the Canadian government broaden scope of longstanding collaboration to accelerate development of VBI's novel, mRNA-launched enveloped virus-like particle vaccine ("MLE") technology platform The
- 2y agoVBIVVIRANTXBrii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial ResultsPR NewswireBrii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health...
- 2y agoVBIVVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesBusiness WireVBI to receive up to $33 million in consideration, subject to achievement of certain activities, for: VBI's manufacturing capabilities and certain related assets at Rehovot manufacturing facility Intellectual
- 2y agoVBIVBrii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial SuppliesPR NewswireBrii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient...
- 3y agoVBIVVBI Vaccines Reports Third Quarter 2023 Financial ResultsBusiness WirePreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023 Continued execution across earlier-stage pipeline, including: Initiation of Phase 2b study of
- 3y agoVBIVVBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine ProgramBusiness WirePreclinical data suggests novel mRNA-launched eVLPs ("MLE") generate significantly enhanced B-cell and T-cell responses compared to mRNA-expression of antigens alone In addition to immunologic benefits, new MLE
- 3y agoVBIVVBI Vaccines' Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of ConcernBusiness WireFirst clinical data from a pan-coronavirus vaccine candidate Elicited high and sustained neutralizing responses against a panel of COVID-19 variants, including Wuhan, Delta, Beta, Omicron BA.5, as well as multiple
- 3y agoVBIVVBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBMBusiness WireMulti-center, randomized, controlled, open-label study to enroll up to 60 patients with first recurrent GBM FDA has granted both Fast Track Designation and Orphan Drug Designation to VBI-1901 in the recurrent
- 3y agoVBIVVBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis BBusiness WireBRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased seroconversion rate is strongly associated with
- 3y agoBRIBYVBIVBrii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis BPR NewswireBRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased HBsAg seroconversion rate is strongly associated with
- 3y agoBRIBYVBIVVIRBrii Biosciences Provides Corporate Updates and Reports 2023 Interim ResultsPR NewswireFirst patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching patients with strong
- 3y agoVBIVVBI Vaccines Reports Second Quarter 2023 Financial ResultsBusiness WirePreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 48% quarter-over-quarter from Q1 to Q2 2023 - redefined, highly targeted commercial field team deployed at the end of Q2 Expanded hepatitis
- 3y agoVBIVVBI Vaccines Announces Closing of Underwriters' Partial Exercise of Option to Purchase Additional Common SharesBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the underwriters of its recent
- 3y agoVBIVVBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in AdultsBusiness WirePreHevbri® is the only approved 3-antigen hepatitis B vaccine for adults in the Netherlands and Belgium Product to be launched via marketing and distribution partner, Valneva VBI Vaccines Inc. (NASDAQ:VBIV)
- 3y agoVBIVVBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct OfferingBusiness WireApproximately $21 million in gross proceeds from underwritten public offering and concurrent registered direct offering add to upfront payment from Brii Biosciences for a combined $33 million to be received by VBI VBI
- 3y agoBRIBYVBIVBrii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to CurePR NewswireExtension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive rights to
- 3y agoANTXBRIBYVBIVVIRBrii Biosciences Provides Latest Clinical Development and Corporate UpdatesPR NewswireCompany extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust
- 3y agoVBIVVBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and WarrantsBusiness WireVBI Vaccines Inc. ((
- 3y agoVBIVVBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus RoyaltiesBusiness WireBrii Biosciences has acquired worldwide exclusive license to VBI-2601 and an exclusive license for PreHevbri® in the Asia Pacific region VBI will receive gross proceeds of $15 million in upfront payments,
- 3y agoBRIBYVBIVVIRBrii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023PR NewswireLate-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment New data show more robust and
- 3y agoVBIVVBI Vaccines Announces Results of Annual General MeetingBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting
- 3y agoVBIVVBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in AdultsBusiness WirePreHevbri® is the only approved 3-antigen hepatitis B vaccine for adults in the U.K. Product to be launched via marketing and distribution partner, Valneva VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a
- 3y agoVBIVVBI Vaccines Announces Poster Presentation at EASL 2023Business WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting T-cell responses and
- 3y agoVBIVVBI Vaccines Reports First Quarter 2023 Financial ResultsBusiness WirePreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 90% quarter-over-quarter from Q4 2022 to Q1 2023 as access to PreHevbrio continues to broaden – now available at several U.S. retail pharmacy
- 3y agoVBIVVBI Vaccines Appoints Vaughn Himes to Board of DirectorsBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief Technical
- 3y agoVBIVVBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock SplitBusiness WireVBI will continue to heavily prioritize making a difference in both prevention and treatment of hepatitis B (HBV) with PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and immunotherapeutic candidate
- 3y agoANTXBRIBYVBIVVIRBrii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial ResultsPR NewswireCompany maintains priority focus on clinical programs to develop a novel functional cure for hepatitis B viral (HBV) infection and a potential first-of-its-kind treatment for postpartum depression (PPD) and major
- 3y agoVBIVVBI Vaccines Reports Full Year 2022 Financial ResultsBusiness WireAccess to PreHevbrio [Hepatitis B Vaccine (Recombinant)] continues to broaden in the U.S. and beyond, with additional approvals received in 2022 in Europe and Canada Clinical data expected throughout 2023 from: (i)
- 3y agoVBIVVBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside ChatBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI's President and CEO, and
- 3y agoVBIVVBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis BBusiness WireBI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and BRII-835 combination induced meaningfully stronger
- 3y agoVBIVVBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in AdultsBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Health Canada has approved PreHevbrio™
- 3y agoVBIVCEPI Boosts 'Coronavirus X' Vaccine Search With Expanded VBI Vaccines DealBusiness WireCEPI and VBI expand scope of partnership to target multiple coronavirus threats Vaccine platform presents multiple antigens, mimicking natural form of the virus The Coalition for Epidemic Preparedness Innovations
- 3y agoVBIVVBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual MeetingBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a
- 4y agoVBIVVBI Vaccines to Participate in Upcoming Investor ConferencesBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that members of the management team will
- 4y agoVBIVVBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual MeetingBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that its abstract highlighting data from the
- 4y agoVBIVVBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateBusiness WireQ3 marked a meaningful quarter for partnerships with a recently announced prophylactic hepatitis B commercialization collaboration in certain European countries with Valneva, and a clinical collaboration in
- 4y agoVBIVVBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) ConferenceBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI's President and CEO, and
- 4y agoAGENVBIVVBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma PatientsGlobeNewswireRandomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022Study expected to assess VBI-1901 with concurrent balstilimab (anti-PD-1) administration in frontline
- 4y agoAGENVBIVVBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma PatientsBusiness Wire- Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022 - Study expected to assess VBI-1901 with concurrent balstilimab (anti-PD-1) administration in
- 4y agoVBIVVBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901Business WireInitiation of first clinical study of multivalent VBI-2901, designed to increase breadth of protection against COVID-19 and related coronaviruses Preclinical data support broadly reactive immunity of VBI-2901 against a panel of coronavirus variant
- 4y agoVBIVVBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV MeetingBusiness WireVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that data from the physician-initiated compassionate use of VBI's 3-antigen hepatitis